Start the conversation
It was the very first stock we recommended on the very first day we published Private Briefing.
It soared as much as 211% and continues to hold 170% above our original recommendation price.
Indeed, each time the stock has backed off, we've re-recommended it.
Now new reports have emerged that say this biotech could well be a takeover target.
The company is Belgium-based Galapagos NV (OTC ADR: GLPYY). And I know from the notes that I received that a lot of you bought this stock. So I wanted to give you the lowdown on this buyout speculation.
This is premium content for Private Briefing subscribers only.